Xenon Pharmaceuticals XENE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$383.17M-52.4% | -$345.91M-47.6% | -$306.33M-43.6% | -$278.23M-39.8% | -$251.45M-33.3% | ||
| $2.47M-6.2% | $2.54M-0.7% | $2.6M— | $2.62M— | $2.63M— | ||
| $58.43M+9.2% | $53.71M+5.9% | $53.19M+14.9% | $52.49M+24.8% | $53.49M+49.5% | ||
| -$1.54M+85.3% | -$3.2M+63.9% | -$10.7M-2,266% | -$10.32M-3,507% | -$10.48M-5,821% | ||
| $7.49M— | $5.51M— | $8.5M— | —— | —— | ||
| —— | —— | $12.01M— | $7.68M— | $1.24M— | ||
| —— | —— | —— | —— | —— | ||
| $1.33M+4.9% | $1.31M+4.7% | $1.3M+4.8% | $1.28M+4.6% | $1.27M+4.0% | ||
| -$1.34M-8.8% | -$1.3M-6.3% | -$1.28M-53.2% | -$1.26M-176% | -$1.23M-1,186% | ||
| —— | —— | -$116K-436% | $250K+409% | $7.83M+5,879% | ||
| -$306.36M-55.6% | -$279.12M-53.9% | -$252.02M-55.2% | -$229.94M-43.0% | -$196.85M-20.9% | ||
| $889K-69.7% | $799K-74.0% | $1.26M-46.7% | $1.57M-47.2% | $2.93M-18.6% | ||
| -$223.79M-192% | $218M+32.1% | $253.8M+246% | $215.77M+280% | $242.7M+221% | ||
| $9.3M+676% | $4.96M+10,457% | $3.62M+41,306% | $1.26M+7,117% | $1.2M+4,464% | ||
| $958.98M+7,121% | $117.11M+865% | $15.71M-95.2% | $13.35M— | $13.28M— | ||
| —— | —— | —— | -$589K— | -$1.42M— | ||
| $429.21M— | $56.45M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $313K+134% | -$73K+90.2% | -$475K— | -$599K— | -$923K— | ||
| -$1.34M-8.8% | -$1.3M-6.3% | -$1.28M-53.2% | -$1.26M-176% | -$1.23M-1,186% | ||
| —— | —— | -$116K— | $250K— | —— | ||
| —— | —— | $12.01M— | $7.68M— | $1.24M— | ||
| $1.33M+4.9% | $1.31M+4.7% | $1.3M+4.8% | $1.28M+4.6% | $1.27M+4.0% | ||
| —— | —— | —— | —— | —— | ||
| $921.64M+2,384% | $112.15M+828% | $87.13M-10.6% | $62.12M-66.0% | $37.1M-86.2% | ||
| —— | $21M+153% | $17.82M+136% | $14.65M+116% | $11.48M+90.9% | ||
| —— | —— | $15.43M+106% | $14.55M+134% | $7.8M+8.3% | ||
| -$1.34M-8.8% | -$1.3M-6.3% | -$1.28M-53.2% | -$1.26M-176% | -$1.23M-1,186% | ||
| $1.73M+3.1% | $1.71M+2.5% | $1.71M+3.5% | $1.7M-2.1% | $1.68M+3.2% | ||
| —— | —— | —— | —— | —— | ||
| -$307.25M-53.8% | -$279.92M-51.7% | -$253.29M-53.7% | -$231.51M-41.3% | -$199.78M-20.0% | ||
| -$307.25M-53.8% | -$279.92M-51.7% | -$253.29M-53.7% | -$231.51M-41.3% | -$199.78M-20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.